Carbon footprint of industry-sponsored late-stage clinical trials.

ABSTRACT:

Objectives

To quantify the carbon footprint from a sample of pharma industry sponsored phase III trials. To develop an approach that can readily be applied to future trials by AstraZeneca and other trial sponsors.

Design

Life cycle assessment including all the sources of carbon emissions associated with a completed, an ongoing and a planned clinical trial. The methodology followed the guidance on appraising the sustainability of Care Pathways, developed by the UK National Health Service in collaboration with parties across the healthcare system.

Setting

Three multicentre late phase trials. One completed heart failure trial, one ongoing oncology trial and one asthma trial with the addition of devices to be representative of current practice.

Participants

The thr

SUBMITTER: Mackillop N 

PROVIDER: S-EPMC10445340 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature